Phase III double-blind study of TAK-536CCB in patients with grade I or II essential hypertension
Phase of Trial: Phase III
Latest Information Update: 25 Sep 2018
At a glance
- Drugs Amlodipine/azilsartan (Primary) ; Amlodipine; Azilsartan
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 14 Apr 2014 Results published in the Clinical Therapeutics.
- 24 Mar 2014 Based on results from this and another phase III trial, NDA was approved in Japan for low dose and high dose combination tablets of amlodipine/azilsartan [Zacras], according to a Takeda media release.
- 02 May 2013 New source identified and integrated: Japan Pharmaceutical Information Center record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History